Sign in
TVTX Stock Price, Chart, Stats & News
Travere Therapeutics, Inc.
Save
Travere Therapeutics, Inc. (TVTX) does not currently pay a dividend.
5.26B
Market cap
–
Current P/E
77.52x
Forward P/E
TVTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 94.20% |
Operating margin | -12.80% |
Pretax margin | -10.04% |
Net margin | -10.24% |
Effective tax rate | -2.01% |
ROA | -8.30% |
ROE | -79.16% |
D/E | 2.96x |
Interest coverage ratio | -5.84x |
TVTX valuation
P/E | – |
P/S | 5.12x |
P/B | 21.43x |
P/CF | 65.12x |
P/FCF | 96.68x |
P/OCF | 65.12x |
PEG | -1.05x |
EV multiple | 102.01x |
About
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression.
Similar securities
Based on sector and market capitalization
Report issue